Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Galectin Therapeutics (GALT) Cash from Investing Activities (2011 - 2014)

Galectin Therapeutics' quarterly Cash from Investing Activities came in at -$400000.0 in Q1 2014, down 814.29% quarter-over-quarter from $56000.0 in Q4 2012.

Galectin Therapeutics has reported Cash from Investing Activities for 3 years, with the latest figure at -$400000.0 in Q1 2014.

  • For the quarter ending Q1 2014, Cash from Investing Activities changed N/A year-over-year to -$400000.0; the trailing twelve-month figure through Dec 2014 stood at -$400000.0 (changed N/A YoY), and the FY2014 full-year result was -$400000.0, changed N/A from the prior year.
  • Cash from Investing Activities for Q1 2014 stood at -$400000.0, down from $56000.0 in the prior quarter.
  • The five-year high for Cash from Investing Activities was $56000.0 in Q4 2012, with the low at -$400000.0 in Q1 2014.
  • Average Cash from Investing Activities over 3 years is -$88500.0, with a median of -$5000.0 recorded in 2011.
  • Peak annual rise in Cash from Investing Activities reached 1220.0% in 2012, while the deepest fall reached 1220.0% in 2012.
  • Tracing GALT's Cash from Investing Activities over 3 years: stood at -$5000.0 in 2011, then jumped by 1220.0% to $56000.0 in 2012, then plunged by 814.29% to -$400000.0 in 2014.
  • The last three Cash from Investing Activities figures came in at -$400000.0 (Q1 2014), $56000.0 (Q4 2012), and -$5000.0 (Q4 2011), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -2.89 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 638.50 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -431.90 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -428.90 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -25.54 Mn
10 Galectin Therapeutics 165.77 Mn 151.67 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2014 -400,000.00
Mar 31, 2014 -400,000.00
Dec 31, 2012 56,000.00
Dec 31, 2012 56,000.00
Dec 31, 2011 -5,000.00
Dec 31, 2011 -5,000.00
Sep 30, 2011 -5,000.00
Sep 30, 2011 -5,000.00